CONSTRUCTION

This index is not yet implemented. Upon completion there will be links in place of the page numbers. In the mean time, you may want to use the search box above left, to look for anything in this document.

A

abortion, spontaneous: 6, 46
activated partial thromboplastin time: 23
activities of daily living (ADL): 29, 35, 41, 44, 45, 69, 88
adrenaline: 14
African American: 10
alcoholism: 56
allele: 12, 13
allergy: 48, 55, 60, 61, 82
alopecia: 3, 15, 27, 32, 56, 60
American College of Rheumatology: 3, 4, 14, 123
amylase, serum: 43
anemia: 3, 4, 7, 21, 27, 28, 35, 36, 39, 60, 62
anger: 7, 29, 30, 42, 65, 66, 75, 84
animal: 11–14, 16
anorexia: 27, 39, 42, 43, 49, 54
antibiotics: 6, 14, 40, 53, 90, 113
anticardiolipin: 3, 22, 35, 45
anticardiolipin antibodies: 23
anticoagulants: 23, 27
anticonvulsants: 53
antihypertensives: 53
antimalarials: 6, 42–44, 55, 56, 57, 85, 105, 113
antinuclear antibodies: 3, 11, 21
antiphospholipid antibodies: 4, 17, 22, 35
anxiety: 29, 41, 61, 75, 76
apoptosis: 13
appetite: 28, 56, 85, 95, 105, 108, 111
arterial thrombosis: 37
arthralgia: 3, 27, 33, 87
arthritis: 2–4, 14, 16, 17, 21, 27, 33, 55, 59, 69, 84, 87, 105, 108, 109, 115
Arthritis Foundation: 8, 124
ascites: 27, 42, 43
Association of Rheumatology Health Professionals: 123
atherosclerosis: 36, 37, 83, 96
autoantibodies: 3, 11–14, 21, 22, 45
azathioprine: 43, 59, 60, 61, 109

B

B cells: 14
baldness (see also alopecia): 89
biologic agents: 16
biopsy:

kidney: 24, 38
skin: 31
bladder cancer: 15
bladder fibrosis: 15
blindness: 41, 44, 85
body hair, increased (see hirsutism)
bone marrow: 35, 60
bruising: 27, 32, 36, 103, 105, 109
butterfly rash (see also malar rash): 27, 31, 32, 89, 129


C

C-reactive protein: 22
Candida: 48
cardiolipin: 23
cardiovascular (see also under specific
disorders)
disease: 49, 96
side effects of drugs: 54, 58
carpal tunnel syndrome: 34, 87
cataracts: 15, 44, 58, 85
CBC: 3, 55, 56, 59–61
CellCept®: 15, 59, 117
children of patients: 7, 66, 67
chloroquine: 55
chlorpromazine: 14
CNS: 27, 40, 41, 45, 83
coagulation: 23
cognitive impairment: 27, 40, 41
combination therapies: 16
complement: 3, 12, 13, 22, 73, 74
congestive heart failure: 58
conjunctivitis: 44
connective tissue disease: 21
contraception: 6, 60
coping skills: 42, 66, 68
coronary artery disease: 15
corticosteroids: 6, 15, 22, 28, 30–32, 35, 38, 42–44, 46, 48, 56–59, 61, 74, 76, 84, 85, 89, 91, 93, 95, 96, 99, 101, 107–109, 111
counseling: 5, 30, 39, 42, 45
creatinine: 23, 24, 39, 54, 61
criteria, American College of
Rheumatology: 4
Cushing’s syndrome: 58
cyclophosphamide: 15–17, 43, 59, 60, 111
cyclosporine: 43, 59, 60, 115
cytoid bodies: 27, 44
cytotoxic: 35, 38, 42

D

dehydroepiandrosterone: 16, 62
depression: 7, 28–30, 32, 41, 42, 49, 58, 65, 68, 75, 76, 83, 84, 108
dermatological (see also rash; skin)
manifestations: 27, 31, 32
nursing interventions: 33
side effects of drugs: 56, 58, 60, 61
dexamethasone: 57
diabetes: 15, 46, 49, 58, 61, 96, 108
diagnosis: 2, 65, 75
dialysis: 38
diclofenac sodium: 54
diet: 4, 5, 28, 30, 33, 37, 39, 43, 48–50, 77, 82, 95, 96, 100, 108
diflunisal: 54
dilute Russell viper venom time: 23
discoid lesions: 89
discoid lupus: 1, 31, 55, 76, 105
discoid rash: 4
diuretics: 53, 90
drug-induced lupus: 2
drugs (see also under specific drugs)
activators of SLE: 2
antibiotics: 6, 14, 40, 53, 90, 113
anticoagulants: 23, 27
anticonvulsants: 53
antihypertensives: 53
antimalarials: 6, 42–44, 55–57, 85, 105, 113
combination therapies: 16
corticosteroids: 6, 15, 22, 28, 30–32, 35, 38, 42–44, 46, 48, 56–59, 61, 74, 76, 84, 85, 89, 91, 93, 95, 96, 99, 101, 107–109, 111
cytotoxics: 35, 38, 42
diuretics: 53, 90
education of patients: 6, 39, 40, 44, 53
immunosuppressives: 6, 15, 29, 48, 59–61, 91, 109
NSAIDs: 6, 35, 42, 54, 55, 57, 93, 103
oral contraceptives: 6, 15, 17, 47
patient history: 2, 5, 6, 20, 55, 57, 58, 60, 61
pregnancy and: 47, 56, 58, 60
salicylates: 42, 55
side effects: 15, 16, 28, 43, 52, 53, 57, 59, 61, 62, 103, 105, 108, 109, 111, 113, 115, 117, 119
treatment plans: 53

E

ecchymoses: 36, 58
edema (see fluid retention)
education of patients (see also Patient Information Sheets)
bleeding prevention: 36
fatigue management: 29, 30
flares: 46
fluid retention: 40
GI manifestations: 43
infection control: 30, 40, 48
joint function: 39
medications: 6, 39, 40, 44, 53
nutrition: 35, 49
pain management: 34
renal complications: 39, 40
skin protection: 33
weight control: 30
emotional
aspects of lupus: 5, 27–29, 41, 61
coping strategies: 68–70
physical repercussions: 67–69
rest: 5
side effects of drugs: 58
support for patients: 7, 30, 65–70
employment: 29
endocarditis: 21
endocrine: 58
environmental factors: 1, 13
epratuzumab: 16
ESR: 3, 22, 27, 35
etanercept: 14
etiology: 11–14, 16
exercise: 4, 28, 30, 33, 34, 37, 77, 79, 82, 84, 88, 95, 96
exophthalmos: 58

F

family issues: 34, 42, 65–69
fas gene: 13
fatigue: 3, 4, 7, 27–29, 35–37, 49, 55, 57, 67, 69, 76, 77, 79, 81, 83, 87, 97, 105, 108, 109, 111
fear: 7, 32, 42, 65–67, 75
Federal Working Group on Lupus: 18
fever: 2, 3, 6, 27–30, 43, 47, 48, 55, 57, 61, 81, 83, 84, 93, 105, 108, 109, 117
flare
allergies and: 49
defined: 1
exercise and: 4, 7
emotion and: 5
fever: 28, 30, 93


131


living with: 68, 69, 81, 89
medication: 6, 15, 16, 48, 54, 113
pregnancy and: 15, 45, 47, 99
symptomatic care: 7, 30
trigger: 13, 81, 115
fluid retention: 5, 28, 40, 54, 103
fluorescent lights: 90
Fluorescent treponemal antibody
absorption (FTA-ABS): 35
FTA-ABS: 35

G

G6PD deficiency: 56
gangrene: 32
gastrointestinal distress
bleeding: 21, 35, 36, 54
effects: 28
interventions: 6, 43, 55, 58
manifestations of lupus: 27, 42
side effects of drugs: 15, 54–56, 58, 60, 61, 95
gastric ulcers: 54
gene therapy: 13
genetics: 11–13, 18, 22, 66
glaucoma: 15, 44, 58, 85, 108
glucose 6-phosphate dehydrogenase
(G6PD) deficiency: 56
glucose, serum: 58
grief: 7, 29, 65, 66

H

hair loss (see alopecia)
halogen lights: 5, 82
hematologic
manifestations of lupus: 27, 35
side effects of drugs: 55, 56, 60
hemorrhagic cystitis: 15, 60
hepatitis: 21
herpes zoster: 48
hirsutism: 32, 58
HLA-DR2: 12
homemaker services: 8
hormones: 11, 13, 14, 16, 57, 62, 84
hormone replacement therapy: 17
human leukocyte antigen: 12
hydralazine: 2, 14
hydrocortisone: 57
hydroxychloroquine sulfate: 55, 113
hyperglycemia: 46, 58
hyperpigmentation: 31
hypertension: 5, 15, 28, 39, 46, 47, 54, 58, 99
hypopigmentation: 31

I

immunization: 6, 48, 82, 93, 113
immunosuppression: 58, 60
immunosuppressives: 6, 15, 29, 48, 59, 60, 61, 91, 109
indomethacin: 54
infection: 4, 6, 15, 16, 28–32, 35, 36, 40, 43, 46–48, 58–62, 81, 82, 89, 93, 97, 108, 109, 111, 113, 115, 117
inflammation: 2, 4, 12, 15, 22, 24, 36, 37, 44, 52, 54, 55, 57–59, 76, 79, 83, 85, 87, 103, 107, 109, 111, 117, 119
inflammatory diseases: 28, 115
infliximab: 14
injury: 41, 42, 44, 45, 82


insomnia: 28, 29, 62
intranuclear nucleic acid: 13
intrauterine devices: 46
intravenous immunoglobulins: 61, 119
isoniazid: 2, 14


J

Jaccoud’s arthropathy: 34


joint pain: 33, 34, 52, 54, 55, 57, 61, 76, 79, 87


K

kaolin clotting time: 23
kidney
biopsy: 24, 38
damage: 38, 109
dialysis: 38
disease: 5, 12, 16, 23, 28, 40, 49, 58, 83, 96, 97
failure: 83
function: 97
glomerular filtration rate: 23
inflammation: 24, 117
side effects of drugs: 46, 59, 108, 115
transplantation: 16, 39
laboratory tests
amylase, serum: 43
ANA: 3, 4, 21
anti-La: 3, 22, 46
anti-Ro: 3, 22, 46
anti-Sm: 3, 4, 22
CBC: 3, 55, 56, 59, 60, 61
coagulation: 23
cortisol levels: 58
complement: 3, 12, 13, 22, 73, 74
C-reactive protein: 22
creatinine clearance: 23, 54
creatinine, serum: 23, 24, 39, 54, 61
ECG: 60, 61
electrolytes: 55, 58
enzyme: 22
ESR: 3, 22, 27, 35
FTA-ABS: 35
G6PD deficiency: 56
glucose, serum: 58
liver function: 56, 60, 61
MHA-TP: 35
platelets: 56, 60
renal function: 60, 61
stool: 55
urine: 23, 55
VDRL: 27, 35
WBC: 60
lesions: 30–33, 37, 38, 48, 54–56, 60, 61, 89
leukocytoclastic vasculitis: 37
leukopenia: 4, 21, 35, 36, 60, 62
Libman-Sacks lesions: 37
lifestyle changes: 30, 75
livedo reticularis: 32
liver: 3, 43, 46, 56, 58–62, 115
lupus anticoagulants: 23, 27
Lupus Foundation of America: 8, 69, 124
lymphopenia: 4, 27


M

malaria: 21, 55
malar rash (butterfly): 4
methotrexate: 43, 59–61, 90, 113
methyldopa: 14
methylprednisolone: 57
periungual erythema: 32
petechiae: 32, 36, 58, 89
phospholipid-binding plasma proteins: 22
photosensitivity: 3–5, 22, 27
physical rest: 4
platelets: 56, 60
pleurisy: 3, 27, 36, 37
pleuropericardial inflammation: 2
polymorphism: 13
prednisone: 15, 16, 21, 35, 57, 107
pregnancy and lactation: 55, 58, 60
complications of lupus: 47
flares: 15, 45, 47, 99
side effects of drugs: 47, 56, 58, 60
premature baby: 46, 99, 101
premature delivery: 6
procainamide: 2, 14
protein-phospholipid complexes: 22
protein/creatinine ratio: 23
pruritus: 39, 56
psychosis: 4, 27, 40, 41, 58
psychosocial factors (see also
emotional): 7, 28, 63, 64
coping skills: 68–70
diagnostic difficulties: 65
family issues: 66–68
pulmonary fibrosis: 60

R

range of motion: 87

rash: 1–5, 13, 31–33, 44–47, 55, 57, 61, 82, 85, 89, 90, 97, 100, 103, 105, 107, 113
Raynaud’s phenomenon: 3, 32, 33, 43, 90, 91, 97
registry and repository: 18
remission: 1, 46, 64, 68, 82, 99, 100, 109
reproduction (see also contraception;
pregnancy and lactation): 6, 14, 15, 17, 45, 58, 60
research advances
etiology of lupus: 11–17
NIAMS role: 17, 18
treatment: 15–17, 70
respiratory: 36, 47
rest: 76, 77, 79, 81–83
emotional: 5
physical: 4
retinal damage: 44, 56, 105
rheumatoid arthritis: 2, 14, 16, 21, 33, 55, 59, 87, 115
ribonucleoprotein complexes: 11, 13
rituximab: 16

S

Safety of Estrogen in Lupus
Erythematosus National Assessment: 17
salicylates: 42, 55
Salmonella: 48
seizures: 3, 4, 27, 40, 41, 47, 83, 84
serositis: 4
Sjogren’s syndrome: 21, 22, 43, 44
skin
biopsy: 31
condition/disease (see also lesion,
rash): 12, 89–91
infection: 28, 48
ulcers: 32, 89
SLE Foundation: 8, 69, 124
smoking: 33, 38, 90
Specialized Centers of Research: 18
spouse/partner of patient: 66, 100
stillbirth: 28, 46, 99
stress: 2, 5, 13, 28, 33, 75, 77, 79, 81, 82, 90, 91
stroke: 27, 40, 84, 96
subacute cutaneous lupus: 31, 32
sunlight: 4, 5, 13, 31, 67, 81, 103
sunscreen: 5, 33, 90
support systems: 7, 8, 31
surgery: 6, 57, 81, 82, 107
systemic sclerosis: 21
symptoms of SLE (see also under specific symptoms): 3, 27–29
cardiopulmonary: 36–38
CNS: 40–42
dermatological: 31–33
gastrointestinal: 42, 43
hematologic: 35, 36
infection: 47, 48
musculoskeletal: 33, 34
nutrition-related: 49, 50
ophthalmologic: 44, 45
psychological: 29
renal: 38–40

T

tendinitis: 34, 87
tendon rupture: 34, 87
tinnitus: 44, 55, 56
treatment of SLE (see also drugs; and under specific regimens): 3–8, 15–17
biologic agents: 15
hormones: 15
thalidomide: 62
thrombocytopenia: 4, 21, 27, 35, 36, 46, 60
thrombosis: 22, 23, 35, 37, 38, 62
tuberculosis: 21, 58

U

ulcers: 32, 89
urinary: 28–30, 39, 40, 48, 54, 58, 60, 117
urticaria: 58

V

vaginal ulcers: 89
valvular heart disease: 27, 37
vasculitis: 27, 37, 40, 42, 43, 61, 89, 119
VDRL: 27, 35
venous thrombosis: 37
vertigo: 41
viruses: 13, 14
visual impairment: 44
VNA: 8
vocational rehabilitation: 8

W

WBC: 21, 24, 27–30, 35, 58, 60
weight changes: 28, 49
weight gain: 5, 15, 28, 29, 39, 58, 67, 76, 95, 100, 108
weight loss: 5, 28, 49, 84, 95, 108
wound healing: 32, 58, 108